The mission of the Experimental Therapeutics and Molecular Pathophysiology (ETMP) Program, part of the Center of Excellence on Mood Disorders, is to conduct clinical (proof of concept studies) and translational (targeted biomarkers of response) research studies on mood and psychotic disorders. The goal is to test new medications that may be more effective and act more rapidly than current standard therapeutics for these conditions. This approach uses biomarkers to predict response to medications, allowing a better understanding of the brain mechanisms involved in therapeutic response in the context of personalized medicine.
Directed by Rodrigo Machado-Vieira, M.D., Ph.D., ETMP uses a wide range of technologies including brain imaging, biochemical, molecular and genetic studies to identify biological signatures of therapeutic response in human studies. Dimensional approaches are also used in research to provide new insights in anhedonia, suicide and other RDoC dimensions. Dr. Machado-Vieira seeks to establish further scientific collaborations with other academic institutions, the National Institutes of Health (NIH) and industry. The program is currently looking for outstanding Postdoctoral Fellows interested in Proof of Concept Trials and Biomarkers.
Rodrigo Machado-Vieira, Ph.D., M.Sc.
Director, Experimental Therapeutics & Molecular Pathophysiology Program
UTHealth Harris County Psychiatric Center (HCPC)
2800 S. MacGregor Way
Houston, TX 77021